| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8785295 | Brachytherapy | 2018 | 10 Pages |
Abstract
Dose attenuation by guidewire is likely the single greatest source of dose attenuation in IVBT in terms of absolute dose reduction and is greater than previously reported for the Novoste Beta-Cath 3.5F. The Novoste Beta-Cath 3.5F delivers an inhomogeneous dose to target. A delivery system is proposed, which resolves the issue of guidewire attenuation in IVBT and should reduce treatment times.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Joseph M. DeCunha, Shirin A. Enger,